DAB2IP and prostate carcinoma: As shown in Figure 6, a dose-dependent inhibition of cell migration was observed in MDA-MB-231 breast cancer cells (Figure 6A), A172-A2 glioma cells (Figure 6B), as well as PC-3 prostate cancer cells that were rendered highly migratory and metastatic via DAB2IP knockdown [45], [46] (PC3-DAB2IP KD, see below) (Figure 6C).